AU2450900A - Therapeutic nucleoside compound - Google Patents

Therapeutic nucleoside compound

Info

Publication number
AU2450900A
AU2450900A AU24509/00A AU2450900A AU2450900A AU 2450900 A AU2450900 A AU 2450900A AU 24509/00 A AU24509/00 A AU 24509/00A AU 2450900 A AU2450900 A AU 2450900A AU 2450900 A AU2450900 A AU 2450900A
Authority
AU
Australia
Prior art keywords
nucleoside compound
therapeutic nucleoside
therapeutic
compound
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24509/00A
Other languages
English (en)
Inventor
Susan Mary Daluge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2450900A publication Critical patent/AU2450900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU24509/00A 1999-02-12 2000-02-11 Therapeutic nucleoside compound Abandoned AU2450900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9903091.8A GB9903091D0 (en) 1999-02-12 1999-02-12 Therapeutic nucleoside compound
GB9903091 1999-02-12
PCT/GB2000/000429 WO2000047581A1 (fr) 1999-02-12 2000-02-11 Compose therapeutique a base de nucleoside

Publications (1)

Publication Number Publication Date
AU2450900A true AU2450900A (en) 2000-08-29

Family

ID=10847550

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24509/00A Abandoned AU2450900A (en) 1999-02-12 2000-02-11 Therapeutic nucleoside compound

Country Status (14)

Country Link
US (1) US6630477B1 (fr)
EP (1) EP1150981B1 (fr)
JP (1) JP2002536448A (fr)
KR (1) KR20010102081A (fr)
CN (1) CN1346356A (fr)
AT (1) ATE237616T1 (fr)
AU (1) AU2450900A (fr)
DE (1) DE60002172T2 (fr)
DK (1) DK1150981T3 (fr)
ES (1) ES2195861T3 (fr)
GB (1) GB9903091D0 (fr)
HK (1) HK1039935B (fr)
PT (1) PT1150981E (fr)
WO (1) WO2000047581A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2368580A1 (fr) * 2006-06-21 2011-09-28 Ge Healthcare As Stabilisation de précurseurs de fluorothymidine
US11583497B2 (en) 2017-11-14 2023-02-21 The Schepens Eye Research Institute, Inc. Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229531B (it) * 1988-01-20 1991-09-04 Univ Minnesota Composti nucleosidi dideossidideidrocarbociclici e formulazione farmaceutica che li contiene
US4916224A (en) * 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
DE68907013D1 (de) * 1988-10-24 1993-07-15 Wellcome Found Guaninderivate mit antiviraler wirkung und deren pharmazeutisch vertraegliche salze.
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
EP0468119A1 (fr) * 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Nouveaux analogues carbocycliques de certains nucléosides
JPH06199812A (ja) * 1991-02-12 1994-07-19 Takeda Chem Ind Ltd 新規シクロペンテン誘導体
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt

Also Published As

Publication number Publication date
ES2195861T3 (es) 2003-12-16
WO2000047581A1 (fr) 2000-08-17
EP1150981B1 (fr) 2003-04-16
ATE237616T1 (de) 2003-05-15
GB9903091D0 (en) 1999-03-31
DE60002172T2 (de) 2003-11-27
CN1346356A (zh) 2002-04-24
KR20010102081A (ko) 2001-11-15
HK1039935B (zh) 2003-12-19
PT1150981E (pt) 2003-08-29
US6630477B1 (en) 2003-10-07
DE60002172D1 (de) 2003-05-22
JP2002536448A (ja) 2002-10-29
HK1039935A1 (en) 2002-05-17
DK1150981T3 (da) 2003-07-21
EP1150981A1 (fr) 2001-11-07

Similar Documents

Publication Publication Date Title
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
TW371660B (en) Therapeutic nucleosides a purine carbocyclic nucleosides for treatment of HIV and HBV infections
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
MY138883A (en) Use of asiatic acid for treatment of cencer
WO2001055111A8 (fr) Composes biaryles, leur preparation et utilisation en therapie
GB0020504D0 (en) Therapeutic method
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
MD990258A (en) Method of treatment of the acute viral hepatitis B
AU2003210659A1 (en) Combination therapy for treatment of hiv infection
NZ512850A (en) Treatment of papillomavirus infections
AU2001236529A1 (en) Combination therapy for cancer
MY124071A (en) Treatment of viral disease in swine
WO2003007876A3 (fr) Conjugues acide amine-acide gras normal et utilisations therapeutiques
AU2450900A (en) Therapeutic nucleoside compound
NZ515173A (en) Treatment of hypersensitivity reaction disorders
AU2002234644A1 (en) Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
EP1347754A4 (fr) Compositions pour la prevention d'une adherence
AU2396900A (en) Treatment and prevention of hiv and other viral infections
WO2003059334A3 (fr) Gemcitabine pour traiter la variole

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase